Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2021
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Research Predicts that Benign Prostatic Hyperplasia (BPH) Drugs Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Overview:
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Benign Prostatic Hyperplasia (BPH) Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Benign Prostatic Hyperplasia (BPH) Drugs Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Benign Prostatic Hyperplasia (BPH) Drugs market in 2020.
Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentation
By Type, Benign Prostatic Hyperplasia (BPH) Drugs market has been segmented into:
Alpha-blocker
Phosphodiesterase Type-5 Inhibitors
5-alpha-Reductase Inhibitors
By Application, Benign Prostatic Hyperplasia (BPH) Drugs market has been segmented into:
Hospitals
Clinics
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Benign Prostatic Hyperplasia (BPH) Drugs market are:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma
1. Market Overview of Benign Prostatic Hyperplasia (BPH) Drugs
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Regions (2015-2020)
1.4 Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Benign Prostatic Hyperplasia (BPH) Drugs Sales Market by Type (2015-2026)
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Type (2015-2020)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Type (2021-2026)
2.3 Alpha-blocker
2.4 Phosphodiesterase Type-5 Inhibitors
2.5 5-alpha-Reductase Inhibitors
3. Covid-19 Impact Benign Prostatic Hyperplasia (BPH) Drugs Sales Market by Application (2015-2026)
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Application (2015-2020)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Application (2021-2026)
3.3 Hospitals
3.4 Clinics
3.5 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Drugs Business
5.1 Astellas Pharma
5.1.1 Astellas Pharma Company Profile
5.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Eli Lilly
5.2.1 Eli Lilly Company Profile
5.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 GlaxoSmithKline
5.3.1 GlaxoSmithKline Company Profile
5.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Sanofi
5.4.1 Sanofi Company Profile
5.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 ADC Therapeutics
5.5.1 ADC Therapeutics Company Profile
5.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Bayer HealthCare
5.6.1 Bayer HealthCare Company Profile
5.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Bristol-Myers Squibb
5.7.1 Bristol-Myers Squibb Company Profile
5.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Valeant Pharmaceuticals
5.8.1 Valeant Pharmaceuticals Company Profile
5.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 Endo Pharmaceuticals
5.9.1 Endo Pharmaceuticals Company Profile
5.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Foresee Pharmaceuticals
5.10.1 Foresee Pharmaceuticals Company Profile
5.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 Madrigal Pharmaceuticals
5.11.1 Madrigal Pharmaceuticals Company Profile
5.11.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.11.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Merck
5.12.1 Merck Company Profile
5.12.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.12.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Novartis
5.13.1 Novartis Company Profile
5.13.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.13.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Spectrum Pharmaceuticals
5.14.1 Spectrum Pharmaceuticals Company Profile
5.14.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.14.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Takeda Pharmaceuticals
5.15.1 Takeda Pharmaceuticals Company Profile
5.15.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.15.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 Teva
5.16.1 Teva Company Profile
5.16.2 Teva Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.16.3 Teva Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.17 Advaxis
5.17.1 Advaxis Company Profile
5.17.2 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.17.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.18 ANI Pharmaceuticals
5.18.1 ANI Pharmaceuticals Company Profile
5.18.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.18.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.19 BHR Pharma
5.19.1 BHR Pharma Company Profile
5.19.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Specification
5.19.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
6.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
7.2 East Asia Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
7.3 East Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
7.4 East Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
8. Europe
8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
8.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
9.2 South Asia Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
9.3 South Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
9.4 South Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
10.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
11.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
11.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
11.4 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
12. Africa
12.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
12.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
12.3 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
12.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
13.2 Oceania Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
13.3 Oceania Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
13.4 Oceania Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
14. South America
14.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
14.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
14.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
14.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2015-2026)
15.2 Rest of the World Benign Prostatic Hyperplasia (BPH) Drugs Key Players in North America (2015-2020)
15.3 Rest of the World Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (2015-2020)
15.4 Rest of the World Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application (2015-2020)
16 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Research Methodology:
Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|